Future cardiology最新文献_第5页

Introducing the use of AngioVac in nonbacterial thrombotic endocarditis: a systematic review. 介绍血管维康在非细菌性血栓性心内膜炎中的应用：系统回顾。

IF 1.6

Future cardiology Pub Date : 2025-04-01 Epub Date: 2025-03-07 DOI: 10.1080/14796678.2025.2476351

Maisha Maliha, Vikyath Satish, Kuan Yu Chi, Amrin Kharawala, Sanjana Nagraj, Tinatin Saralidze, Nathaniel Abittan, Natalia Nazarenko, Gal Rubinstein, Riya Patel, Seth I Sokol, Robert T Faillaice, Leonidas Palaiodimos

{"title":"Introducing the use of AngioVac in nonbacterial thrombotic endocarditis: a systematic review.","authors":"Maisha Maliha, Vikyath Satish, Kuan Yu Chi, Amrin Kharawala, Sanjana Nagraj, Tinatin Saralidze, Nathaniel Abittan, Natalia Nazarenko, Gal Rubinstein, Riya Patel, Seth I Sokol, Robert T Faillaice, Leonidas Palaiodimos","doi":"10.1080/14796678.2025.2476351","DOIUrl":"10.1080/14796678.2025.2476351","url":null,"abstract":"Introduction: Nonbacterial thrombotic endocarditis (NBTE) involves vegetations on heart valves without active bloodstream infection. The AngioVac device, a vacuum-based aspiration system commonly used for infective endocarditis, has potential in managing NBTE, particularly in patients unsuitable for surgery. This study systematically reviews the literature to evaluate AngioVac's effectiveness in reducing vegetations in NBTE.Methods: A systematic literature review was conducted using PubMed, Embase, Cochrane, and Web of Science databases through February 2024. Primary outcome was procedural success, defined as a ≥ 50% reduction in vegetation size on transesophageal echocardiogram. Secondary outcomes included in-hospital mortality, hospital stay length, and procedural complications.Results: Out of 38 identified articles, 4 case reports met inclusion criteria. Patients were male with a median age of 60 years, and NBTE was associated with conditions such as lung adenocarcinoma, end-stage renal disease, and antiphospholipid syndrome. The mitral valve was the most commonly affected site. AngioVac achieved 100% procedural success, with no complications or in-hospital mortality. The average hospital stay was 2 days. Follow-up revealed one patient alive at 2 months, one deceased at 3 months and no data for two patients.Conclusion: AngioVac is a promising tool for safely reducing vegetations in NBTE, especially for high-risk surgical candidates.The study design and protocol are registered with PROSPERO International Prospective Register of Systematic Reviews (registration number CRD42024505295).","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"305-313"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment options for heart failure in individuals with overweight or obesity: a review. 超重或肥胖患者心力衰竭的治疗方案综述

IF 1.6

Future cardiology Pub Date : 2025-04-01 Epub Date: 2025-03-18 DOI: 10.1080/14796678.2025.2479378

Athina Nasoufidou, Panagiotis Stachteas, Paschalis Karakasis, Christos Kofos, Efstratios Karagiannidis, Aleksandra Klisic, Djordje S Popovic, Theocharis Koufakis, Nikolaos Fragakis, Dimitrios Patoulias

{"title":"Treatment options for heart failure in individuals with overweight or obesity: a review.","authors":"Athina Nasoufidou, Panagiotis Stachteas, Paschalis Karakasis, Christos Kofos, Efstratios Karagiannidis, Aleksandra Klisic, Djordje S Popovic, Theocharis Koufakis, Nikolaos Fragakis, Dimitrios Patoulias","doi":"10.1080/14796678.2025.2479378","DOIUrl":"10.1080/14796678.2025.2479378","url":null,"abstract":"Obesity and heart failure are interlaced global epidemics, each contributing to significant morbidity and mortality. Obesity is not only a risk-factor for heart failure, but also complicates its management, by distinctive pathophysiological mechanisms and cumulative comorbidities, requiring tailored treatment plan. To present current treatment options for heart failure in individuals with overweight/obesity, emphasizing available pharmacological therapies, non-pharmacological strategies, and the management of related comorbidities. We conducted a comprehensive literature review regarding the results of heart failure treatments in individuals with overweight/obesity, including cornerstone interventions as well as emerging therapeutic options. Specific drug classes, including angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, have demonstrated consistent efficacy in heart failure irrespective of body mass index, while diuretics remain a key for fluid management. Glucagon-like peptide-1 receptor agonists have shown promising results in improving relevant outcomes and warrant further research. Non-pharmacological approaches, including weight-loss strategies and lifestyle modifications, have shown to improve symptoms, exercise tolerance and quality of life. Managing heart failure in individuals with overweight/obesity requires a multidisciplinary, individualized approach integrating pharmacological and non-pharmacological options. Emerging therapies and preventive strategies arise to address the unique challenges in this population and provide improved outcomes.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"315-329"},"PeriodicalIF":1.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First experience with a new tool for automatic mapping of fragmented signals in a case report of cardioneuroablation. 在心脏神经消融术的病例报告中，首次使用一种新的工具来自动映射碎片信号。

IF 1.6

Future cardiology Pub Date : 2025-04-01 Epub Date: 2025-03-09 DOI: 10.1080/14796678.2025.2476313

Helge Haarmann, Besir Hasan, Nibras Soubh, Eva Rasenack, Simon Schlögl, Markus Zabel, Leonard Bergau

引用次数: 0

Correction. 修正。

IF 1.6

Future cardiology Pub Date : 2025-03-26 DOI: 10.1080/14796678.2025.2483603

引用次数: 0

An unexpected battle with peripartum cardiomyopathy: a case report. 意外的围产期心肌病之战：1例报告。

IF 1.6

Future cardiology Pub Date : 2025-03-01 Epub Date: 2025-02-28 DOI: 10.1080/14796678.2025.2472590

Bryan Tornabene, David Waldron, Hannah Short, Nicholas Duca

引用次数: 0

Comparative efficacy of single-coil versus dual-coil ICD leads: a meta-analysis of clinical outcomes. 单线圈与双线圈ICD导联的比较疗效：临床结果荟萃分析

IF 1.6

Future cardiology Pub Date : 2025-03-01 Epub Date: 2025-01-30 DOI: 10.1080/14796678.2025.2459542

Muhammad Hamza Shuja, Syed Hasan Shuja, Fabeeha Shaheen, Ramish Hannat, Firzah Shakil, Abeera Farooq Abbasi, Minal Hasan

{"title":"Comparative efficacy of single-coil versus dual-coil ICD leads: a meta-analysis of clinical outcomes.","authors":"Muhammad Hamza Shuja, Syed Hasan Shuja, Fabeeha Shaheen, Ramish Hannat, Firzah Shakil, Abeera Farooq Abbasi, Minal Hasan","doi":"10.1080/14796678.2025.2459542","DOIUrl":"10.1080/14796678.2025.2459542","url":null,"abstract":"Background: Implantable cardioverter-defibrillators (ICDs) are essential for reducing sudden cardiac death in patients at risk of ventricular arrhythmias. The choice of ICD lead - single-coil or dual-coil - can influence device performance and patient outcomes. This meta-analysis evaluates the comparative efficacy and safety of single-coil versus dual-coil ICD leads to inform clinical decision-making.Methods: A systematic search of PubMed, Cochrane Library, and Google Scholar was performed up to October 2024. Only randomized controlled trials (RCTs) comparing single-coil and dual-coil ICD leads were included. Outcomes assessed included defibrillation threshold (DFT), first-shock efficacy, all-cause mortality, cardiovascular mortality, shock impedance, and peak current.Results: Seven RCTs involving 1,614 patients were analyzed. Single-coil leads demonstrated superior first-shock efficacy (OR: 1.60; p = 0.05), reduced all-cause mortality (RR: 0.63; p = 0.02), and better peak current (MD: -2.29; p = 0.02). DFT and cardiovascular mortality were comparable between groups, while dual-coil leads exhibited lower shock impedance (MD: 18.26; p < 0.00001).Conclusions: Single-coil ICD leads are associated with improved first-shock efficacy and reduced all-cause mortality, suggesting their potential superiority in certain patient populations. Further research is warranted to refine lead selection criteria.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"167-175"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of amino acids and protein administration in preventing cardiac surgery-associated acute kidney injury. 氨基酸和蛋白质在预防心脏手术相关急性肾损伤中的作用。

IF 1.6

Future cardiology Pub Date : 2025-03-01 Epub Date: 2025-02-08 DOI: 10.1080/14796678.2025.2463271

Alice Bottussi, Jacopo D'Andria Ursoleo, Viviana Teresa Agosta, Monica De Luca, Fabrizio Monaco

{"title":"The role of amino acids and protein administration in preventing cardiac surgery-associated acute kidney injury.","authors":"Alice Bottussi, Jacopo D'Andria Ursoleo, Viviana Teresa Agosta, Monica De Luca, Fabrizio Monaco","doi":"10.1080/14796678.2025.2463271","DOIUrl":"10.1080/14796678.2025.2463271","url":null,"abstract":"Acute kidney injury (AKI) persists as one of the most common complications after cardiac surgery. Beyond being burdened by high morbidity and mortality rates, effective therapeutic options are still lacking. To date, the management of cardiac surgery-associated AKI (CSA-AKI) mainly focuses on preventive strategies, e.g. the implementation of standardized care bundles. Interestingly, recent experimental studies have suggested a potential nephroprotective role for both amino acids (AA) and proteins. As such, these compounds show multiple beneficial renal effects, spanning enhancement of renal blood flow, improved oxygenation, and recruitment of renal functional reserve. Moreover, clinical studies have investigated the therapeutic potential of single AA, AA combinations, and proteins. A recent large multicenter randomized controlled trial showed reduced AKI incidence in cardiac surgery patients receiving intravenous AA supplementation. However, these interventions have not yet demonstrated beneficial effects on major clinical outcomes, such as survival. Given the well-established AA safety profile and the underlying biological rationale supporting their use, this review summarizes the existing literature on the effects of various formulations and combinations of perioperative AA and protein on renal outcomes when administered in cardiac surgery patients.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"191-202"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11875465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evinacumab for children with homozygous familial hypercholesterolemia: a plain language summary. Evinacumab治疗纯合子家族性高胆固醇血症儿童：简单的语言总结

IF 1.6

Future cardiology Pub Date : 2025-03-01 Epub Date: 2025-02-11 DOI: 10.1080/14796678.2025.2461425

Albert Wiegman, Robert Pordy

引用次数: 0

Reconsidering the role of beta-blockers in post-myocardial infarction patients with preserved ejection fraction. 重新考虑-受体阻滞剂在保留射血分数的心肌梗死后患者中的作用。

IF 1.6

Future cardiology Pub Date : 2025-03-01 Epub Date: 2025-02-14 DOI: 10.1080/14796678.2025.2465214

Sidra Kalsoom, Muhammad Adnan Zaman

引用次数: 0

The role of physical exercise in cancer therapy-related CV toxicity. 体育锻炼在癌症治疗相关CV毒性中的作用。